Saad Z. Usmani, MD, MBA, FACP

The current rationale for managing a patient with newly diagnosed multiple myeloma with consolidation therapy post-transplant.

Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.

Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.

Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.